Date: 2016-12-13
Type of information: Collaboration agreement
Compound: software solution to support commercial availability of T-cell therapies
Company: Kite Pharma (USA - CA) Vitruvian Networks (USA - CA)
Therapeutic area: Technology - Services
Type agreement: collaboration
Action mechanism:
Disease:
Details: * On December 13, 2016, Kite Pharma and Vitruvian Networks, a pioneering cell and gene therapy software and analytics platform company co-founded by GE Ventures and the Mayo Clinic , announced a strategic partnership to create a software solution to support commercial availability of T-cell therapies. Together, the parties will design and develop a platform for patients, physicians and treatment centers that enables commercial-scale ordering, logistics, monitoring and delivery of autologous cell therapies if they are FDA -approved, including axicabtagene ciloleucel (formerly known as KTE-C19) for aggressive non-Hodgkin lymphoma. Under the terms of the agreement, both parties will contribute resources and relevant experience to the partnership. Further terms of the agreement were not disclosed.
Financial terms:
Latest news:
